It is noteworthy that the deletion of CDKN2A and CDKN2B, key regulators of Cdk4/6 expression, occurs in ~50% of bladder cancers, as this indicates that many MI-BC patients may be responsive to Cdk4/6 inhibitors [49]. This evidence concerns the gene CDK4 and urinary bladder carcinoma.